Notícias e Atividades da Outlook Therapeutics

Outlook Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Outlook Therapeutics é uma empresa listada sob o símbolo OTLK (US).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Outlook Therapeutics

• Lawrence Kenyon, Chief Executive Officer and Director
• Julian Gangolli, Director
• Randy Thurman, Chairman of the Board

Recentes movimentos de executivos em Outlook Therapeutics

• Russell Trenary, President, Chief Executive Officer and Director, deixou a Companhia  (Notícia publicada em 4 de dezembro de 2024).
• Lawrence Kenyon antes Chief Financial Officer and Director, agora é Chief Executive Officer and Director  (Notícia publicada em 4 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Outlook Therapeutics.

Outlook Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Outlook Therapeutics

• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Press Releases - Outlook Therapeutics, Inc.
• Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1 - Outlook Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Outlook Therapeutics

• Outlook Therapeutics na Wikipedia, Google News e Yahoo Finance
• Outlook Therapeutics na LinkedIn, Twitter e YouTube